Stephen Jolles, Mark R Stein, Hilary J Longhurst, Michael Borte, Bruce Ritchie, Matthias H Sturzenegger, Melvin Berger
Subcutaneous immunoglobulin (SCIG) treatment provides stable serum immunoglobulin G (IgG) levels, is associated with fewer systemic adverse events than intravenous immunoglobulin (IVIG) treatment, and offers the convenience of home therapy. In clinical practice, IVIG is still used preferentially for initiation of treatment in newly diagnosed patients with primary immunodeficiency (PI) and for immunomodulatory therapy, such as treatment of peripheral neuropathies, when high doses are believed to be necessary...
2011: Biologics in Therapy